| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.77B | 7.10B | 7.09B | 7.39B | 7.11B | 7.34B |
| Gross Profit | 2.99B | 3.19B | 3.02B | 2.87B | 2.49B | 3.18B |
| EBITDA | 1.33B | 1.40B | 736.00M | 577.00M | 928.00M | 1.20B |
| Net Income | 791.00M | 810.00M | 280.00M | 149.00M | 462.00M | 710.00M |
Balance Sheet | ||||||
| Total Assets | 5.53B | 5.56B | 5.75B | 5.95B | 6.16B | 6.33B |
| Cash, Cash Equivalents and Short-Term Investments | 166.00M | 167.00M | 202.00M | 367.00M | 183.00M | 319.00M |
| Total Debt | 3.08B | 2.88B | 2.90B | 2.92B | 3.10B | 3.17B |
| Total Liabilities | 5.39B | 5.08B | 5.26B | 5.56B | 5.43B | 5.74B |
| Stockholders Equity | -22.00M | 321.00M | 328.00M | 220.00M | 556.00M | 411.00M |
Cash Flow | ||||||
| Free Cash Flow | 636.00M | 761.00M | 483.00M | 930.00M | 535.00M | 945.00M |
| Operating Cash Flow | 853.00M | 981.00M | 695.00M | 1.16B | 786.00M | 1.28B |
| Investing Cash Flow | -217.00M | -94.00M | -175.00M | -223.00M | -229.00M | -452.00M |
| Financing Cash Flow | -746.00M | -924.00M | -655.00M | -753.00M | -689.00M | -1.39B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $20.23B | 26.84 | 18.59% | 1.38% | 1.45% | 42.04% | |
69 Neutral | $333.43B | 20.90 | 31.90% | 2.92% | 1.23% | 17.97% | |
63 Neutral | $63.71B | 22.40 | 450.35% | 2.67% | -0.05% | 2.49% | |
63 Neutral | $33.11B | 16.96 | 136.87% | 5.03% | -10.04% | -23.41% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | $39.15B | -41.67 | -20.73% | 1.30% | -6.36% | -554.84% | |
55 Neutral | $11.96B | 15.27 | 4163.16% | 5.05% | -9.35% | 123.06% |
On November 19, 2025, The Clorox Company conducted its virtual annual meeting of shareholders, where all company nominees for director were elected, executive officer compensation was approved on an advisory basis, and Ernst & Young LLP was ratified as the independent auditor for the fiscal year ending June 30, 2026. These decisions reflect shareholder support for the company’s current leadership and strategic direction, potentially impacting its governance and operational stability.
On November 3, 2025, Clorox reported a 19% decrease in net sales for the first quarter of fiscal year 2026, primarily due to the impact of its ERP transition, which led to lower shipments as retailers depleted their inventories. The ERP transition, while causing temporary disruptions, marks a significant milestone in Clorox’s transformation journey, with the company now focusing on accelerating growth through innovation and demand-creation initiatives.
On October 27, 2025, Eric Reynolds, the Executive Vice President and Chief Operating and Strategy Officer of Clorox, announced his resignation after 27 years with the company. He will officially step down on December 2, 2025, but will remain available in an advisory capacity until February 2, 2026. Clorox does not plan to appoint a replacement for his position, which may impact the company’s strategic operations.